• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.

作者信息

Göhring G, Lange K, Hofmann W, Nielsen K V, Hellström-Lindberg E, Roy L, Morgan M, Kreipe H, Büsche G, Giagounidis A, Schlegelberger B

出版信息

Leukemia. 2012 Feb;26(2):356-8. doi: 10.1038/leu.2011.193. Epub 2011 Jul 29.

DOI:10.1038/leu.2011.193
PMID:21799512
Abstract
摘要

相似文献

1
Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.来那度胺治疗的5q缺失骨髓增生异常综合征患者的端粒缩短、克隆进化与疾病进展
Leukemia. 2012 Feb;26(2):356-8. doi: 10.1038/leu.2011.193. Epub 2011 Jul 29.
2
Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.来那度胺治疗仅7天后，一名患有骨髓增生异常综合征且5号染色体长臂缺失患者的血液学和细胞遗传学反应。
Leuk Res. 2011 Sep;35(9):e175-6. doi: 10.1016/j.leukres.2011.05.020. Epub 2011 Jun 11.
3
The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.定义早期骨髓增生异常综合征伴5q缺失患者的疾病进展模式存在困难，因此需要新的预后标志物。
Leuk Res. 2014 Mar;38(3):287-8. doi: 10.1016/j.leukres.2013.12.013. Epub 2013 Dec 26.
4
A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).一例伴有5号染色体长臂缺失（del(5q)）和20号染色体长臂缺失（del(20q)）的骨髓增生异常综合征患者对极短疗程来那度胺治疗的延迟但持久的反应及意外的克隆重新分布
Leuk Res. 2009 Nov;33(11):e199-202. doi: 10.1016/j.leukres.2009.06.009. Epub 2009 Jul 9.
5
Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.伴 del(5q)骨髓增生异常综合征患者接受来那度胺治疗后的形态学分析：一项日本多机构研究。
Leuk Res. 2012 May;36(5):575-80. doi: 10.1016/j.leukres.2011.11.011. Epub 2011 Dec 15.
6
Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.接受来那度胺治疗后未能获得持续红细胞或细胞遗传学缓解的 del(5q) MDS 患者，其克隆进化和 AML 进展的风险增加。
Ann Hematol. 2010 Apr;89(4):365-74. doi: 10.1007/s00277-009-0846-z. Epub 2009 Oct 24.
7
Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.停用来那度胺的del(5q)骨髓增生异常综合征患者的长期输血独立性
Leukemia. 2012 Apr;26(4):855-8. doi: 10.1038/leu.2011.268. Epub 2011 Sep 30.
8
Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.来那度胺在 del(5q) 骨髓增生异常综合征疗效中的多效作用机制。
Expert Rev Anticancer Ther. 2010 Oct;10(10):1663-72. doi: 10.1586/era.10.135.
9
Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.来那度胺治疗伴有孤立性5号染色体长臂缺失（del(5q)）和JAK2 V617F突变的骨髓增生异常综合征患者的疗效
Leuk Res. 2011 Sep;35(9):1276-8. doi: 10.1016/j.leukres.2011.06.008. Epub 2011 Jul 20.
10
Unusual clonal evolution involving 5q in a case of myelodysplastic syndrome with deletion 5q 31 treated with lenalidomide.来那度胺治疗的伴有5q31缺失的骨髓增生异常综合征病例中涉及5q的异常克隆演变
Haematologica. 2008 Feb;93(2):315-6. doi: 10.3324/haematol.11917.

引用本文的文献

1
Influence of Cytogenetics on the Outcome of Patients With High-Risk Myelodysplastic Syndrome Including Deletion 5q Treated With Azacitidine With or Without Lenalidomide.细胞遗传学对高危骨髓增生异常综合征患者（包括伴有或不伴有来那度胺的阿扎胞苷治疗的5q缺失患者）预后的影响
Genes Chromosomes Cancer. 2025 Feb;64(2):e70029. doi: 10.1002/gcc.70029.
2
Telomere biology: from disorders to hematological diseases.端粒生物学：从疾病到血液学疾病
Front Oncol. 2023 May 19;13:1167848. doi: 10.3389/fonc.2023.1167848. eCollection 2023.
3
Short Dysfunctional Telomere Is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients.
短功能失调端粒高度预示骨髓增生异常综合征患者的不良预后，但对急性髓系白血病患者则不然。
Int J Hematol Oncol Stem Cell Res. 2020 Jul 1;14(3):188-199. doi: 10.18502/ijhoscr.v14i3.3728.
4
Prognostic Markers of Myelodysplastic Syndromes.骨髓增生异常综合征的预后标志物。
Medicina (Kaunas). 2020 Jul 27;56(8):376. doi: 10.3390/medicina56080376.
5
Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion.5q 缺失的骨髓增生异常综合征患者复杂核型的克隆进化途径。
Int J Mol Sci. 2018 Oct 21;19(10):3269. doi: 10.3390/ijms19103269.
6
Dysregulation of Telomere Lengths and Telomerase Activity in Myelodysplastic Syndrome.骨髓增生异常综合征中端粒长度和端粒酶活性的失调
Ann Lab Med. 2017 May;37(3):195-203. doi: 10.3343/alm.2017.37.3.195.
7
Short telomere length and its correlation with gene mutations in myelodysplastic syndrome.骨髓增生异常综合征中短端粒长度及其与基因突变的相关性。
J Hematol Oncol. 2016 Jul 28;9(1):62. doi: 10.1186/s13045-016-0287-9.
8
Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia.诱导骨髓增生异常肿瘤中端粒功能障碍和表观遗传改变引起的染色体不稳定性。
Cancers (Basel). 2013 Jul 4;5(3):857-74. doi: 10.3390/cancers5030857.
9
Lenalidomide: a review of its use in patients with transfusion-dependent anaemia due to low- or intermediate-1-risk myelodysplastic syndrome associated with 5q chromosome deletion.来那度胺：治疗伴有 5q 染色体缺失的低危或中危-1 级骨髓增生异常综合征相关输血依赖型贫血的研究进展。
Drugs. 2013 Jul;73(11):1183-96. doi: 10.1007/s40265-013-0071-x.
10
Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletion.来那度胺治疗伴有 5q 染色体缺失的骨髓增生异常综合征患者的疗效和安全性。
Ther Adv Hematol. 2012 Apr;3(2):105-16. doi: 10.1177/2040620711435659.